Determination of nitrofurantoin and fosfomycin susceptibility among urinary Escherichia coli isolates

Rachana Kanaujia, Amit Kumar, Malay Bajpai


Background: Urinary tract infections (UTIs) are one of the most common infections. For treatment of UTIs, there are limited antibiotics due to increased resistance among uropathogens. Two older antibiotics; Nitrofurantoin and Fosfomycin have become novel oral therapeutic options against uropathogens. Aim of the study was to identify UTI causing micro-organisms and evaluate in-vitro activity of nitrofurantoin and fosfomycin against most common isolated organism (E. coli).

Methods: Results of urine samples culture and susceptibility testing over a period of 1 year were analysed and included in this study.

Results: Micro-organisms were isolated from 568 urine samples. Most commonly isolated organism was Escherichia coli (40.50%), followed by Klebsiella spp. (20.07%) and Staphylococcus spp. (17.07%). Susceptibility of E. coli to nitrofurantoin and fosfomycin was 91.74% and 65.65% respectively.

Conclusion: Good activity of nitrofurantoin and fosfomycin against E. coli indicates that these two drugs are potential therapeutic alternatives for urinary tract infections.


Urinary tract infections, E. coli, Nitrofurantoin, Fosfomycin

Full Text:



Ahmed MA, Shukla GS, Bajaj HK. Incidence of Urinary Tract Infections and determination of their susceptibility to antibiotics among Pregnant Women. Int J Cell Sci Biotechnol. 2016;5:12-6.

Kothari A, Sagar V. Antibiotic resistance in pathogens causing community-acquired urinary tract infections in India: a multicenter study. J Infect Dev. 2008;2(5):354-8.

Pardeshi P. Prevalence of urinary tract infections and current scenario of antibiotic susceptibility pattern of bacteria causing UTI. Indian J Microbiol Res. 2018;5(3):334-8.

Chaudhari VL. Profile and antimicrobial susceptibility pattern of urinary bacterial isolates at a tertiary care hospital in central india Biomedical European of profile and antimicrobial susceptibility pattern of urinary. 2016;3(7):2-6.

Patel H, Soni S, Bhagyalaxmi A, Patel N. Causative agents of urinary tract infections and their antimicrobial susceptibility patterns at a referral center in Western India: An audit to help clinicians prevent antibiotic misuse. J Fam Med Prim Care. 2019;8(1):154.

6. Sardar A, Basireddy SR, Navaz A, Singh M, Kabra V. Comparative evaluation of fosfomycin activity with other antimicrobial agents against E.Coli isolates from urinary tract infections. J Clin Diagnostic Res. 2017;11(2):DC26-DC29.

Gardiner BJ, Stewardson AJ, Abbott IJ, Peleg AY. Nitrofurantoin and fosfomycin for resistant urinary tract infections: Old drugs for emerging problems. Aust Prescr. 2019;42(1):14-9.

Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India. Ann Clin Microbiol Antimicrob. 2007;6:1-7.

Karishetti M, Shaik H. Clinicomicrobial assessment of urinary tract infections in a tertiary care hospital. Indian J Heal Sci Biomed Res. 2019;12(1):69.

Banerjee S, Sengupta M, Sarker T. Fosfomycin susceptibility among multidrug-resistant, extended-spectrum beta-lactamase-producing, carbapenem-resistant uropathogens. Indian J Urol. 2017;33(2):149.

Vijayganapathy S, Karthikeyan V, Mallya A, Mythri K, Viswanatha R, Keshavamurthy R. Antimicrobial resistance patterns in a tertiary care nephro-urology center in South India. J Integr Nephrol Androl. 2018;5(3):93.

Prakash D, Saxena RS. Distribution and Antimicrobial Susceptibility Pattern of Bacterial Pathogens Causing Urinary Tract Infection in Urban Community of Meerut City, India. ISRN Microbiol. 2013;1-13.

Maraki S, Samonis G, Rafailidis PI, Vouloumanou EK, Mavromanolakis E, Falagas ME. Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother. 2009;53(10):4508-10.

Udayan D, Khan S, Pullanhi U, Kumar A. Fosfomycin as a promising alternative to treat urinary tract infection due to multidrug resistant uropathogens. Turkish J Urol. 2018;44(6):515.